drugset / Trial / NCT01870778

Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in AHF

NCT01870778

Phase 3 Completed 6600 enrolled Novartis Pharmaceuticals
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of the study was to evaluate the efficacy, safety and tolerability of intravenous infusion of serelaxin, when added to standard therapy, in acute heart failure (AHF) patients.

Timeline

Start
2013-10-02
Primary completion
2017-01-23
Completion
2017-02-01

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Serelaxin Protein / enzyme biologic 30 ug/kg Intravenous

Indications